Evidence map›Paper›PMID 27095855›Full record

ReviewIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India

Pharmacovigilance in radiopharmaceuticals.

Rishi Kumar, Vivekanandan Kalaiselvan, Rakesh Kumar, Ravendra Verma, Gyanendra Nath Singh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. The Global Perspective of Pharmacovigilance in Nuclear Medicine Practice.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
  2. Inclusion of Radiopharmaceuticals in the Indian Pharmacopeia: A Step Forward.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rishi KumarPharmacovigilance Division, Indian Pharmacopoeia Commission, National Coordination Centre-Pharmacovigilance Programme of India, India.
Vivekanandan KalaiselvanPharmacovigilance Division, Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh, India.
Rakesh KumarPharmacovigilance Division, Indian Pharmacopoeia Commission, National Coordination Centre-Pharmacovigilance Programme of India, India.
Ravendra VermaPharmacovigilance Division, Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh, India.
Gyanendra Nath SinghPharmacovigilance Division, Indian Pharmacopoeia Commission, Ghaziabad, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indian Pharmacopoeia Commission is Committed for maintaining the standards of drugs including Radiopharmaceuticals (RPs) by publishing Indian Pharmacopoeia. These RPs are being used in India for diagnostic or therapeutic purpose. RPs though contain relatively small quantities of active ingredient and administered in small volumes could cause some adverse reactions to the patients. The objective of presenting this article is to introduce the system of adverse drug reaction reporting to the nuclear medicine fraternity who are dealing with RPs.

Indexed as

Adverse drug reactionspharmacovigilanceradiopharmaceuticals

Identifiers

PMID27095855
PMCPMC4815399
OpenAlexW2293518465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.